Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Bitwise Ethereum Strategy ETF (AETH)

Bitwise Ethereum Strategy ETF (AETH)
27.30 unch (unch) 11:38 ET [NYSE Arca]
27.31 x 3 27.39 x 7
Realtime by (Cboe BZX)
27.31 x 3 27.39 x 7
Realtime - - (-) -
Quote Overview for Wed, Apr 9th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
27.18
Day High
27.33
Open 27.31
Previous Close 27.30 27.30
Volume 2,387 2,387
Avg Vol 1,884 1,884
Stochastic %K 1.65% 1.65%
Weighted Alpha -40.15 -40.15
5-Day Change -0.16 (-0.60%) -0.16 (-0.60%)
52-Week Range 27.16 - 52.00 27.16 - 52.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Price/Earnings ttm N/A
  • Annual Dividend & Yield 5.46 (19.94%)
  • Most Recent Dividend 5.458 on 12/26/24
  • Management Fee 0.85%

Options Overview Details

View History
  • Implied Volatility 63.73% ( -2.15%)
  • Historical Volatility 22.76%
  • IV Percentile 33%
  • IV Rank 20.37%
  • IV High 99.83% on 08/05/24
  • IV Low 54.49% on 06/07/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 4
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 49
  • Open Int (30-Day) 47

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.16 +0.07%
on 04/09/25
Period Open: 31.28
31.39 -13.41%
on 03/12/25
-4.10 (-13.12%)
since 03/10/25
3-Month
27.16 +0.07%
on 04/09/25
Period Open: 32.72
32.89 -17.36%
on 01/13/25
-5.54 (-16.93%)
since 01/10/25
52-Week
27.16 +0.07%
on 04/09/25
Period Open: 46.68
52.00 -47.73%
on 12/06/24
-19.50 (-41.77%)
since 04/10/24

Most Recent Stories

More News
These 3 Quirky ETFs May Be Strong Plays in 2025

Heading into an uncertainty for the markets in 2025, investors may be looking to make big bold moves—or to strike a balance with defense. These ETFs do both.

FLYU : 25.23 (-19.85%)
HCMT : 25.66 (-5.38%)
AETH : 27.18 (-0.44%)
Ethereum ETFs: Buy the Dip, or Steer Clear?

Ethereum, valued at $318 billion by market cap, is the second-largest cryptocurrency in the world and has already delivered game-changing returns to shareholders.

^ETHUSD : 1,510.797 (-9.47%)
^BTCUSD : 79,388.55 (-4.45%)
^SOLUSD : 110.2035 (-8.26%)
^MATICUS : 0.17619 (-2.63%)
^OPETH : 0.0004200 (+4.74%)
EETH : 28.19 (-8.01%)
EFUT : 19.63 (-4.24%)
AETH : 27.18 (-0.44%)
21Shares Unveils S&P Risk Controlled Bitcoin and Ethereum Index ETPs

As part of the Crypto Winter Suite, the ETPs seek to limit cryptocurrencies’ volatility by tracking the S&P Bitcoin Dynamic Rebalancing Risk Control...

SE : 115.48 (-3.03%)
BTCS : 1.4400 (-4.00%)
AETH : 27.18 (-0.44%)
21Shares Announces Crypto Winter Suite

Products are intended to meet consumer needs in the bear market, with the 21Shares Bitcoin Core ETP launched as the first offering in the Crypto Winter...

SE : 115.48 (-3.03%)
BTCS : 1.4400 (-4.00%)
AETH : 27.18 (-0.44%)
21Shares Releases Sixth State of Crypto Report: Crypto Assets Portfolio Allocation

21Shares Releases Sixth State of Crypto Report: Crypto Assets Portfolio Allocation The State of Crypto Report provides an in-depth look at the crypto...

SE : 115.48 (-3.03%)
BTCS : 1.4400 (-4.00%)
AETH : 27.18 (-0.44%)
21Shares Launches USDY, the World’s First USD Yield ETP

21Shares Launches USDY, the World’s First USD Yield ETP The 21Shares USD Yield ETP provides investors collateralized dollar-denominated yield at the...

SE : 115.48 (-3.03%)
BTCS : 1.4400 (-4.00%)
AETH : 27.18 (-0.44%)
Investing in the DeFi revolution: 21Shares launches Layer 1 and DeFi ETPs

Investing in the DeFi revolution: 21Shares launches Layer 1 and DeFi ETPs 21Shares Launches First DeFi ETP in Europe and Layer 1 Index ETP With...

SE : 115.48 (-3.03%)
BTCS : 1.4400 (-4.00%)
AETH : 27.18 (-0.44%)
Tom McDonough Joins Netography’s Board of Directors

Netography , the security company for the Atomized Network, today announced that Tom McDonough has joined the company’s Board of Directors as an independent board member. The appointment follows Netography’s...

AETH : 27.18 (-0.44%)
21Shares Announces the Listing of Three New Crypto ETPs on Euronext Paris and Amsterdam

Zurich, February 17, 2022 – 21Shares AG (“21Shares”), the world’s largest issuer of cryptocurrency ETPs, today announced the x-listing of three new crypto...

SE : 115.48 (-3.03%)
AETH : 27.18 (-0.44%)
21Shares Announces the Listing of Decentraland and FTX Token on BX Swiss

February 10, 2022 – 21Shares AG (“21Shares”), the world’s largest issuer of cryptocurrency ETPs, today announced the listing of two new world's first...

SE : 115.48 (-3.03%)
AETH : 27.18 (-0.44%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 4.54 (-0.66%)
EyePoint Provides Company Update and Anticipated Development Milestones for 2025

EYPT : 4.54 (-0.66%)
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

EYPT : 4.54 (-0.66%)
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference

EYPT : 4.54 (-0.66%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 4.54 (-0.66%)
EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUCIA Trial for DURAVYU in Wet AMD

EyePoint Pharmaceuticals initiates LUCIA trial for DURAVYU, evaluating efficacy in wet AMD with data expected in 2026.Quiver AI SummaryEyePoint Pharmaceuticals announced that the first patient has been...

EYPT : 4.54 (-0.66%)
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

EYPT : 4.54 (-0.66%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 4.54 (-0.66%)
EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EYPT : 4.54 (-0.66%)
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments

EYPT : 4.54 (-0.66%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 4.54 (-0.66%)
EyePoint Provides Company Update and Anticipated Development Milestones for 2025

EYPT : 4.54 (-0.66%)
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

EYPT : 4.54 (-0.66%)
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference

EYPT : 4.54 (-0.66%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 4.54 (-0.66%)
EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUCIA Trial for DURAVYU in Wet AMD

EyePoint Pharmaceuticals initiates LUCIA trial for DURAVYU, evaluating efficacy in wet AMD with data expected in 2026.Quiver AI SummaryEyePoint Pharmaceuticals announced that the first patient has been...

EYPT : 4.54 (-0.66%)
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

EYPT : 4.54 (-0.66%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 4.54 (-0.66%)
EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EYPT : 4.54 (-0.66%)
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments

EYPT : 4.54 (-0.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Fund Summary

The Bitwise Ethereum Strategy ETF seeks to invest in cash-settled, front-month Ether Futures Contracts.

See More

Top 10 Holdings

Name % Holdings

See More

Key Turning Points

3rd Resistance Point 27.55
2nd Resistance Point 27.45
1st Resistance Point 27.37
Last Price 27.18
1st Support Level 27.19
2nd Support Level 27.09
3rd Support Level 27.01

See More

52-Week High 52.00
Fibonacci 61.8% 42.51
Fibonacci 50% 39.58
Fibonacci 38.2% 36.65
Last Price 27.18
52-Week Low 27.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.